Adults 60 to 85, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in WAB-AQ ScorePrimary· 12 weeks post-treatment
The primary outcome measure will be the change in score on the Western Aphasia Battery Aphasia Quotient (WAB-AQ), a score assessing overall aphasia recovery. Scores can range from 0-100, with higher scores representing better outcomes. 0-25 is very severe, 26-50 is severe, 51-75 is moderate, and 76-above is mild. A score of 93 or higher is considered recovered.
Group
Value
95% CI
Active TMS
-1.7
± 4.3
Sham TMS
-.1
± 7.3
Change in Percentage of Items Correct on the PNTSecondary· 12 weeks post-treatment
The secondary outcome measure will be change in naming accuracy on the Philadelphia Naming Test (PNT). PNT naming accuracy is measured as a percentage from 0% to 100% with higher percentages meaning better naming ability. The task involves naming 175 pictures of common objects.
Group
Value
95% CI
Active TMS
-3.2
± 8.2
Sham TMS
-5.0
± 6.1
Adverse events — posted to ClinicalTrials.gov
Time frame: From baseline, adverse event data were collected over a period of time consisting of 12 weeks..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Impaired verbal communication is a cardinal symptom of Alzheimer Disease (AD) and the source of enormous distress and disability. Effective therapies for this deficit are lacking. In light of the emerging literature demonstrating that Transcranial Magnetic Stimulation (TMS) improves general cognition in subjects with Alzheimer Disease (AD), the investigators propose to study the effectiveness of TMS as a therapy for impaired verbal communication. The hypothesis to be tested is that TMS combined with Constraint Induced Language Therapy (CILT) improves verbal communication more than sham TMS and CILT. A second aim is to use state-of-the-art neuroimaging to understand the mechanisms underlying any beneficial effect of the treatment.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD
· NA
· not yet recruiting
NCT06320366 — Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder
· NA
· recruiting
NCT05857137 — Psychosis TMS Study
· NA
· active not recruiting
NCT03651700 — Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Chronic Aphasia
· Phase 2
· completed
NCT02205918 — Brain-Behavior Interactions in Tic Suppression
· completed
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
NCT07290387 — Tele-Savvy for Latino Caregivers
· NA
· recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
· NA
· recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease
· NA
· recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
· Phase 3
· recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
· NA
· recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
· EARLY_PHASE1
· not yet recruiting
NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD
· NA
· not yet recruiting
NCT07489430 — DaxibotulinumtoxinA for Blepharospasm
· Phase 2
· not yet recruiting
NCT07463131 — Negative Income Tax Trial
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
Last refreshed: 15 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04482179.